Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol 2017; 23(36): 6571-6592 [PMID: 29085206 DOI: 10.3748/wjg.v23.i36.6571]
Corresponding Author of This Article
Luigi Elio Adinolfi, MD, Professor, Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, University of Campania, “L. Vanvitelli”, Piazza Miraglia, 80100 Naples, Italy. luigielio.adinolfi@unicampania.it
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Amedeo Lonardo, Fabio Nascimbeni, Mauro Maurantonio, Alessandra Marrazzo, Azienda Ospedaliero-Universitaria di Modena, Ospedale Civile di Baggiovara, 41126 Modena, Italy
Fabio Nascimbeni, Alessandra Marrazzo, University of Modena and Reggio Emilia, 41126 Modena, Italy
Luca Rinaldi, Luigi Elio Adinolfi, Department of Medical, Surgical, Neurological, Geriatric, and Metabolic Sciences, University of Campania “Luigi Vanvitelli”, 80100 Naples, Italy
Author contributions: Lonardo A, Nascimbeni F and Adinolfi LE contributed to conception, designed the study, partially wrote the manuscript and made critical revision of the manuscript; Maurantonio M, Marrazzo A and Rinaldi L partially wrote the manuscript; all the authors approved the final version of the manuscript; Lonardo A and Nascimbeni F contributed equally.
Conflict-of-interest statement: There are no conflicts of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Luigi Elio Adinolfi, MD, Professor, Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, University of Campania, “L. Vanvitelli”, Piazza Miraglia, 80100 Naples, Italy. luigielio.adinolfi@unicampania.it
Telephone: +39-81-5665081 Fax: +39-81-5665081
Received: July 14, 2017 Peer-review started: July 15, 2017 First decision: August 10, 2017 Revised: August 21, 2017 Accepted: September 5, 2017 Article in press: September 5, 2017 Published online: September 28, 2017 Processing time: 73 Days and 2 Hours
Core Tip
Core tip: Nonalcoholic fatty liver disease (NAFLD) is a pandemic disease. Recent evidence highlights new concepts in clinical and pathogenic heterogeneity of NAFLD, a systemic disorder with a multifactorial pathogenesis and protean clinical manifestations. Other than the classical obese phenotype of NAFLD, a lean though metabolically abnormal variant has been recognized. Simple steatosis is no more considered a benign condition; insulin resistance is necessary but not sufficient for the disease progression, and NAFLD is not only a mere hepatic manifestation of metabolic syndrome, but may forerun the development of metabolic syndrome and cardio-renal complications. Several non-invasive diagnostic tests are now available and new drug treatment options are coming.
